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AbstrAct
Objective to compare the real- word effectiveness of 
subcutaneous tocilizumab (tcZ- Sc) and intravenous 
tocilizumab (tcZ- iV) in rheumatoid arthritis (ra).
Methods Patients with ra with tcZ from eight european 
registries were included. Drug retention was compared 
using unadjusted Kaplan- Meier and cox models adjusted 
for baseline patient, disease and treatment characteristics, 
using a strata term for year of treatment initiation and 
country of registry. the proportions of patients achieving 
clinical Disease activity index (cDai) remission and low 
disease activity (lDa) at 1 year were compared using 
samples matched on the same covariates and corrected 
for attrition using lUnDeX.
Results 3448 patients were retrieved, 2414 with tcZ- iV 
and 1034 with tcZ- Sc. crude median retention was 3.52 
years (95% ci 3.22 to 3.85) for tcZ- iV and 2.12 years for 
tcZ- Sc (95% ci 1.88 to 2.38). in a country- stratified and 
year of treatment initiation–stratified, covariate- adjusted 
analysis, hazards of discontinuation were similar between 
tcZ- Sc and tcZ- iV treated patients (Hr 0.93, 95% ci 
0.80 to 1.09). the average adjusted cDai change at 1 year 
was similar in both groups (−6.08). after matching, with 
560 patients in each group, cDai remission corrected for 
attrition at 1 year was also similar between tcZ- Sc and 
tcZ- iV (10.4% in tcZ- iV vs 12.8% in tcZ- Sc (difference: 
2.4%, bootstrap 95% ci −2.1% to 7.6%)), but cDai lDa 
was lower in tcZ- iV patients: 41.0% in tcZ- iV versus 
49.1% in tcZ- Sc (difference: 8.0 %; bootstrap 95% ci 
2.4% to 12.4%).
Conclusion With similar retention and effectiveness, 
tcZ- Sc is an adequate alternative to tcZ- iV for ra. When 
possible, considering the costs of the tcZ- iV route, tcZ- Sc 
should be the preferred mode of administration.
InTROduCTIOn
Rheumatoid arthritis (RA) is a chronic 
autoimmune joint disease characterised by 
joint inflammation that may lead to struc-
tural damage. Since the development of 
biologic disease- modifying antirheumatic 
drugs (bDMARDs), its management and 
outcome have significantly changed with 
an important increase in the number of 
treatments available to achieve the desired 
target.1 Tocilizumab (TCZ) is a human-
ised anti- IL-6 receptor antibody that signifi-
cantly decreases disease activity and inhibits 
structural damage, improving the patient’s 
outcome.2 3 Intravenous TCZ (TCZ- IV) has 
been licensed in Europe in 2009 for the 
management of patients with RA refractory 
to conventional synthetic (cs)DMARDs and 
tumour necrosis factor inhibitors, followed 
by the approval of subcutaneous (TCZ- SC) 
formulation in 2014.4 The efficacy and safety 
of TCZ- SC has been studied in different 
clinical trials. In BREVACTA, TCZ- SC was 
compared with placebo and had significantly 
greater efficacy on American College of 
Key messages
What is already known about this subject?
 ► in randomised controlled trials of patients with rheu-
matoid arthritis, subcutaneous tocilizumab has been 
shown to be non- inferior to its intravenous formula.
What does this study add?
 ► in this real- world setting register study with unse-
lected patients with rheumatoid arthritis, subcutane-
ous tocilizumab and intravenous tocilizumab show 
comparable effectiveness. Switching from one mode 
of delivery to another did also not seem to alter 
effectiveness.
How might this impact on clinical practice?
 ► When possible, considering the costs of the intrave-
nous route, subcutaneous tocilizumab should be the 
preferred mode of administration.
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Rheumatology (ACR) response rates and joint damage 
inhibition.5 In the MUSASHI clinical trial, 348 patients 
were randomised to receive either TCZ- SC or TCZ- IV in 
a double- blind design. The results showed that TCZ- SC 
was non- inferior to TCZ- IV in terms of efficacy and 
adverse events.6 In SUMMACTA, TCZ- SC was compared 
with TCZ- IV in 1262 patients with a 1:1 randomisa-
tion.7 At 97 weeks, the proportions of patients achieving 
ACR 20/50/70 responses and Disease Activity Score 28 
(DAS28) remission were comparable in the two treatment 
arms.7 However, to our knowledge, the efficacy of these 
two modes of administration has not been compared in 
a real- world setting. Thus, the objective of this observa-
tional study is to evaluate the effectiveness of TCZ- IV 
and TCZ- SC in terms of retention and disease activity in 
patients with RA across eight European registries.
MeTHOds
The TOCERRA collaboration of registries (TOcilizumab 
Collaboration of European Registries in RA) is an inves-
tigator- led project aiming at evaluating clinical aspects of 
TCZ use in patients with RA, supported by the industry, 
which has been described elsewhere.8 9 This study 
restricted the sample to the registries from the collabo-
ration that contributed both TCZ- IV and TCZ- SC treated 
patients and thus comprised data from eight countries: 
Czech Republic (ATTRA), Finland (ROB- FIN), Italy 
(GISEA), Norway (NOR- DMARD), Portugal ( Reuma. pt), 
Slovenia ( BioRx. si), Spain (BIOBADASER) and Switzer-
land (SCQM). All patients starting treatment with TCZ 
between 1 January 2009 and 15 March 2018 were consid-
ered eligible for the present study. Inclusion criteria were 
diagnosis of RA established by a rheumatologist and base-
line information on the mode of delivery.
exposure of interest
The main exposure of interest was the mode of adminis-
tration of TCZ (subcutaneous vs intravenous).
study outcomes
Our main outcomes were drug retention and disease 
activity in terms of Clinical Disease Activity Index (CDAI) 
following initiation of TCZ. A secondary outcome was the 
disease activity in terms of DAS28.
Drug retention is supposed to reflect both effective-
ness and tolerance of a drug and is reliably assessed in 
all registries.10 11 It was defined as the time from the start 
date of TCZ treatment until the treatment discontinua-
tion date plus 1 month, as we estimated that the treat-
ment was still effective during this time. If treatment had 
not been discontinued, we censored retention at the date 
of the last reported follow- up visit.
CDAI and DAS28 were analysed both as a contin-
uous outcome over time and as a measure of remission 
(CDAI ≤2.8, DAS28 <2.6) or low disease activity (LDA, 
2.8<CDAI≤10, 2.6≤DAS28<3.2) at 1 year.12–15 Considering 
the frequency of assessments in most of the registries, 
shorter evaluations of remission or LDA were not possible.
Covariates
The baseline covariates considered were sex, age, ever 
smoking, Body Mass Index (BMI) as a continuous vari-
able and as a categorical variable (BMI<25, 25 ≤ BMI<30, 
BMI ≥ 30), disease duration, seropositivity (presence 
of rheumatoid factor (RF) or anticyclic citrullinated 
peptide antibodies (ACPA)), previously used bDMARDs, 
concomitant csDMARDs, use of glucocorticoids (GC) 
and daily dosage, functional disability (Health Assess-
ment Questionnaire, HAQ), markers of disease activity 
(CDAI, DAS28), inflammation markers (erythrocyte sedi-
mentation rate (ESR), C reactive protein (CRP)), pres-
ence of comorbidities (cardiovascular disease, interstitial 
lung disease, infection, malignancy and/or neuropsychi-
atric disorder), year of treatment initiation and country 
of registry. We did not adjust for level of education in 
the models as this covariate was missing for 57.8% of 
patients in the main analysis and completely missing in 
two registers. To limit misclassification of exposure and 
assign seronegative status to patients with missing data, 
seropositivity was defined as positive if RF and/or ACPA 
were positive according to each national registry, nega-
tive if both were negative and missing if one was missing 
and the other was negative.
statistical methods
Baseline characteristics across delivery mode were 
compared using χ2 test for categorical variables and 
Wilcoxon rank- sum test for continuous variables. We 
analysed drug retention with Kaplan- Meier and Cox 
models. In the Cox models, the baseline hazards were 
allowed to vary by country of registers and year of treat-
ment initiation. A post hoc analysis adjusting instead of 
stratifying for year of treatment initiation was added to 
explore its effect. A cluster term was added to account 
for patients with multiple courses of tocilizumab. Missing 
covariates were imputed using multiple imputations 
with chained equations, using 50 samples. CDAI and 
DAS28 change over time were analysed with mixed- 
effects models for longitudinal data, with a cubic effect 
of time, but Spain register was excluded for this anal-
ysis because of some key information missing. Because 
of collinearity between CDAI and DAS28, CRP and ESR, 
glucocorticoid use and dose, only CDAI, ESR and GC 
use were used for the models. The frequency of disease 
remission or LDA under treatment was assessed at 1 year 
post- treatment start. When no observed values within a 
3- month window were available, they were imputed using 
a quadratic interpolation for each patient. We estimated 
the proportions of patients reaching remission or LDA 
by treatment group using proportions and compared 
them with the χ2 test. We also corrected for drug discon-
tinuation using the LUNDEX index (index combining 
the proportion of patients fulfilling specific response 
criteria with the proportion of patients still adhering to 
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therapy).16 The advantage of this index is that it inte-
grates clinical response as well as adherence to therapy 
in a composite value. Thus, it avoids the selection only 
of patients who are still under treatment, excluding 
those who stopped for example for ineffectiveness or 
an adverse event and therefore resulting in a selection 
bias in favour of responders, which may overestimate 
drug effectiveness. To compare the LUNDEX between 
groups while adjusting for covariates, we also matched 
on a 1:1 basis the TCZ- SC and TCZ- IV population using 
a propensity score estimated on the same covariates as 
for the Cox model, except for CDAI, HAQ and ESR that 
were matched exactly after categorisation, with a calliper 
width of 0.2 of the pooled SD of the logit of the propen-
sity score. CIs around the differences in LUNDEX- 
corrected remission or LDA rates were computed using 
bootstrap with 10 000 bootstrap samples. We did two 
sensitivity analyses: one taking into account only patients 
after the introduction in the market of TCZ- SC (2014) 
and another analysing separately patients depending on 
whether they switched or not their route of administra-
tion (which yielded four groups: TCZ- SC only, TCZ- IV 
only, TCZ- SC2IV for patients switching from TCZ- SC 
to TCZ- IV and TCZ- IV2SC for patients switching from 
TCZ- IV to TCZ- SC). All analyses and tabulations were 
performed using R V.3.4.2 with the mice, Survival, lme4, 
lmertest and Matching packages.
ResulTs
A total of 3448 patients were retrieved before 15 March 
2018, including 2414 with TCZ- IV and 1034 with TCZ- SC 
at baseline. All the registries contributed patients to both 
the TCZ- IV and TCZ- SC groups. Baseline demographics 
were similar between the groups, and there was no differ-
ence in the number of previous bDMARDs, but patients 
in the TCZ- IV group had more often methotrexate only 
than other csDMARDs or combination of csDMARDs and 
more severe baseline disease characteristics, including 
higher DAS28, HAQ, tender joint count (TJC), swollen 
joint count (SJC), ESR and CRP than patients treated 
with TCZ- SC (table 1). There were more patients with 
higher levels of education in the TCZ- SC population. For 
patients with TCZ- SC, the majority had 162 mg every 2 
weeks. Only 2 patients had TCZ- SC every 10 days, 2 every 
3 weeks and 31 every month. For patients with TCZ- IV, 
the majority of patients had a dose of 8 mg/kg with 
54 patients who had a dose of 4 mg/kg. The standard 
interval was every 4 weeks with one patient who had 
TCZ- IV every 2 weeks and two every 3 weeks. Patient char-
acteristics of the sensitivity analysis are available in online 
supplementary tables S1 and S2. In the TCZ- SC2IV group 
comprising only 18 patients, they could not be included 
in the discontinuation and disease activity analyses, and 
the TCZ- IV2SC population could also not be included in 
the bootstrap analysis, including only 274 patients.
Crude median retention (figure 1) was 3.52 years (95% 
CI 3.22 to 3.85) for TCZ- IV and 2.12 years for TCZ- SC 
(95% CI 1.88 to 2.38). Crude retention was not signifi-
cantly different between categories of BMI. In a country- 
stratified and year of treatment initiation–stratified, 
covariate- adjusted analysis, we found that hazards of 
discontinuation were similar among patients on TCZ- SC 
compared with patients on TCZ- IV (HR 0.93, 95% CI 
0.80 to 1.09; table 2). Higher CDAI, higher HAQ and 
presence of GC at baseline were associated with greater 
risk of discontinuation; combination therapy with any 
csDMARDs, and in particular the combination of MTX 
or MTX and at least one other csDMARD, was associated 
with reduced risk of discontinuation, but not combina-
tion therapy of TCZ with other csDMARDs than MTX 
(table 2). The HR strongly swayed to 1 after stratification 
by year of treatment initiation, suggesting that this was 
the most important confounding factor linked to the 
difference in treatment discontinuation between TCZ- SC 
and TCZ- IV (online supplementary table S3). To explore 
this effect of year of treatment initiation, we added a post 
hoc analysis adjusting for calendar year (instead of strati-
fying) that showed increasing HR of discontinuation with 
more recent years (online supplementary table S3).
When looking at the year of prescription, there was 
a progressive increase in the use of TCZ- SC compared 
with TCZ- IV with more patients initiating TCZ- SC than 
TCZ- IV since 2015 (table 1, last rows). In the first sensi-
tivity analysis taking only patients starting TCZ since 2014, 
the crude median retention was still higher in TCZ- IV, 
although the difference was less important (2.79 years, 
95% CI 2.28 to 3.16 vs 2.01 years, 95% CI 1.80 to 2.27 for 
TCZ- SC) (online supplementary figure S1). After adjust-
ment, the hazards of discontinuation were similar (HR 
1.00, 95% CI 0.85 to 1.17). In this subset, absence of GC 
at baseline, co- therapy with MTX or MTX and at least 
another csDMARD at baseline were also associated with 
reduced risk of discontinuation. In the second sensitivity 
analysis, the crude median retention was still significantly 
higher between TCZ- IV only (3.12 years, 95% CI 2.76 to 
3.47) and TCZ- SC only (2.12 years, 95% CI 1.89 to 2.38), 
and was even higher for TCZ- IV2SC (7.94 years, 95% 
CI 6.96 to NA, the upper endpoint of the 95% CI never 
reaching 50% of discontinuation) (online supplemen-
tary figure S2). After adjustment, the hazards of discon-
tinuation when comparing TCZ- SC only to TCZ- IV only 
were not significantly different (HR 0.95, 95% CI 0.81 
to 1.11 for TCZ- SC only). However, when comparing 
TCZ- IV- only patients to TCZ- IV2SC patients, hazards of 
discontinuation were still lower in the switching group 
(HR 0.65, 95% CI 0.56 to 0.76).
CDAI score and DAS28 decreased over time, faster 
initially before plateauing at around 2 years, for both 
modes of TCZ administration (figure 2, table 3 and 
online supplementary table S4). The average adjusted 
CDAI (p=0.12) and its evolution (p=0.38) was not signifi-
cantly different between groups and the difference of 
CDAI between baseline and 1 year was −6.08. The average 
adjusted DAS28 was slightly lower in the TCZ- SC group 
(−0.15, 95% CI −0.26 to −0.05, p=0.004), but its evolution 
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Table 1 Baseline characteristics
N=3448 TCZ- IV n=2414 n TCZ- SC n=1034 n P values
Total no of visits 
(median (IQR))
4 (2–8) 2 (1–4)
Total patient- years 5606.0 1273.5
Age, years (median 
(IQR))
56.6 (47.7–64.5) 2414 57.3 (48.6–65.3) 1034 0.17
Female gender, n 
(%)
1923 (79.7) 2414 850 (82.2) 1034 0.09
Ever smoker 456 (32.1) 1420 202 (29.0) 696 0.16
BMI (median (IQR)) 25.6 (22.6–29.1) 1950 26.2 (23.1–29.6) 719 0.02
Disease duration, 
years (median (IQR))
6.2 (2.7–12.3) 1950 6.7 (2.8–13.0) 747 0.39
Seropositivity (RF 
and/or ACPA), n (%)




  None 692 (30.5) 319 (33.1)
  1 921 (40.6) 387 (40.1)
  2 474 (20.9) 185 (19.2)
  ≥3 179 (7.9) 73 (7.6)








  None 675 (28.5) 284 (27.8)
  MTX 960 (40.5) 317 (31.1)
  MTX+other 
csDMARDs
295 (12.4) 175 (17.2)
  Other than MTX 442 (18.6) 244 (23.9)
DAS28 (median 
(IQR))
4.4 (3.4–5.9) 2414 4.1 (3.3–5.5) 1034 <0.001
CDAI (median (IQR)) 17.0 (13.5–28.4) 2414 17.0 (15.0–24.7) 1034 0.1
HAQ (median (IQR)) 1.1 (0.9–1.7) 2414 1.0 (1.0–1.5) 1034 0.02
TJC (over 28 joints) 
(median (IQR))
8.0 (3.0–14.0) 1933 6.0 (2.0–11.0) 887 <0.001
SJC (over 28 joints) 
(median (IQR))
6.0 (2.0–10.0) 1936 4.0 (2.0–8.0) 890 <0.001
PGA (median (IQR)) 57.0 (10.0–80.0) 1653 60.0 (25.0–78.0) 646 0.24
PhGA (median 
(IQR))
40.0 (6.0–68.0) 1540 40.0 (13.5–60.0) 639 0.98
ESR (mm/hour) 
(median (IQR))
27.0 (10.0–46.0) 1770 22.0 (10.0–41.0) 658 0.02
CRP (mg/L) (median 
(IQR))
9.0 (3.0–25.8) 1921 6.7 (2.0–19.3) 863 <0.001
Education category 1101 361 0.03
  0–10 years 394 (35.8) 127 (35.2)
  11–13 years 538 (48.9) 158 (43.8)
  >13 years 169 (15.3) 76 (21.1)
Continued
 on M










pen: first published as 10.1136/rm






5lauper K, et al. RMD Open 2018;4:e000809. doi:10.1136/rmdopen-2018-000809
Rheumatoid arthritis
N=3448 TCZ- IV n=2414 n TCZ- SC n=1034 n P values
Comorbidities 1310 (61.5) 2129 524 (58.4) 897 0.12
No of patients for each route of delivery since 2014 by year of treatment initiation
2014 348 (80.9 %) 82 (19.1%)
2015 260 (41.9%) 361 (58.1%)
2016 183 (35.3%) 336 (64.7%)
2017–2018 91 (28.7%) 226 (71.3%)
ACPA, anti–citrullinated protein antibody; BMI, body mass index; CDAI, Clinical Disease Activity Index; DAS28, Disease Activity Score 28; 
ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IQR, interquartile range; MTX, methotrexate; PGA, patient 
global assessment; PhGA, Physician global assessment; RF, rheumatoid factor; SJC, swollen joint counts; TCZ- IV, intravenous tocilizumab; 
TCZ- SC, subcutaneous tocilizumab; TJC, tender joint counts; bDMARDs, biological disease- modifyingantirheumatic drugs; csDMARDs, 
conventional synthetic disease- modifying antirheumatic drugs.
Table 1 Continued
Figure 1 Unadjusted Kaplan- Meier curves of drug 
discontinuation by route of administration. TCZ, tocilizumab; 
TCZ- IV, intravenous tocilizumab; TCZ- SC, subcutaneous 
tocilizumab.
Table 2 Multivariable analysis of drug discontinuation
HR 95% CI P values
TCZ- IV – – –
TCZ- SC 0.93 0.80 to 1.09 0.37
Age, years 1.00 1.00 to 1.00 0.85
Female gender 0.96 0.84 to 1.09 0.54
Disease duration, years 1.00 1.00 to 1.01 0.32
Seropositivity 0.89 0.77 to 1.03 0.12
BMI 1.01 1.00 to 1.02 0.22
Ever smoking 1.11 0.97 to 1.28 0.14
Glucocorticoids 1.16 1.03 to 1.31 0.02
Concomitant csDMARD 
(base=none)
0.88 0.78 to 0.98 0.03
  Any csDMARD MTX 0.87 0.76 to 1.00 0.04
  MTX+other 
csDMARDs
0.79 0.66 to 0.94 0.008
  Other than MTX 0.97 0.84 to 1.12 0.67
Previous bDMARDs 
(base=none)
  1 1.06 0.94 to 1.20 0.37
  2 1.10 0.94 to 1.29 0.25
  ≥3 1.10 0.88 to 1.38 0.39
CDAI at baseline 1.01 1.00 to 1.02 0.001
HAQ at baseline 1.14 1.04 to 1.26 0.008
ESR 1.00 1.00 to 1.00 0.53
Comorbidities 0.99 0.87 to 1.13 0.87
bDMARD, biological disease- modifying antirheumatic drug; 
BMI, Body Mass Index; csDMARD, conventional synthetic 
disease- modifying antirheumatic drug; CDAI, Clinical Disease 
Activity Index; ESR, erythrocyte sedimentation rate; HAQ, 
Health Assessment Questionnaire; MTX, methotrexate; TCZ- IV, 
intravenous tocilizumab; TCZ- SC, subcutaneous tocilizumab.
was not statistically different (p=0.16). Presence of GC, 
presence of a concomitant csDMARD, higher HAQ and 
higher ESR at baseline were associated with higher CDAI 
and DAS28 at any time during follow- up. Seropositivity 
was associated with a lower CDAI and DAS28 at any time 
during follow- up. Female gender was associated with 
higher DAS28 at any time during follow- up. The results 
were similar in the sensitivity analysis taking only patients 
starting TCZ since 2014 except that in the 2014 and after 
subset, the presence of concomitant csDMARD at base-
line was no longer significantly associated with higher 
CDAI and DAS28 at any time during follow- up and that 
BMI was statistically associated with a slightly higher 
CDAI and DAS28 at any time during follow- up (data not 
shown). The average adjusted CDAI and its evolution also 
did not significantly differ between TCZ- IV only, TCZ- SC 
only, TCZ- IV only and TCZ- IV2SC.
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Figure 2 Multivariable analysis of Clinical Disease Activity 
Index (CDAI) over time modelled with a cubic effect of time 
and adjusted for age, gender, disease duration, seropositivity, 
Body Mass Index, smoking, presence of glucocorticoids, 
presence and type of concomitant conventional synthetic 
disease- modifying antirheumatic drugs (DMARDs), 
number of previous biologic DMARDs, Health Assessment 
Questionnaire score, erythrocyte sedimentation rate and 
presence of a comorbidity at baseline. TCZ- IV, intravenous 
tocilizumab; TCZ- SC, subcutaneous tocilizumab.
Table 3 Multivariable analysis of CDAI over time
Overall
Coeff 95% CI P values
Treatment at baseline
  TCZ- IV – –
  TCZ- SC −0.76 −1.70 to 0.19 0.12
Time, years −8.19 −8.87 to −7.51 <0.001
Time- squared 2.29 2.05 to 2.54 <0.001
Time- cubed −0.18 −0.21 to −0.16 <0.001
Age, years −0.02 −0.06 to 0.01 0.22
Female gender −0.54 −1.66 to 0.58 0.34
Disease duration, years −0.01 −0.07 to 0.05 0.72
Seropositivity −1.85 −3.01 to −0.70 0.002
BMI 0.03 −0.05 to 0.12 0.45
Smoking −0.32 −1.20 to 0.55 0.47
Glucocorticoids 1.68 1.01 to 2.34 <0.001
Concomitant csDMARD 
(base=none)
1.04 0.41 to 1.68 0.001
  Any csDMARD MTX 1.51 0.81 to 2.21 <0.001
  MTX+other 
csDMARDs
0.70 −0.60 to 2.00 0.29
  Other than MTX −0.07 −1.04 to 0.90 0.88
Previous bDMARDs 
(base=none)
  1 0.42 −0.63 to 1.48 0.43
  2 0.80 −0.36 to 1.96 0.18
  ≥3 0.06 −1.63 to 1.74 0.95
HAQ at baseline 3.87 3.25 to 4.50 <0.001
ESR 0.25 0.24 to 0.27 <0.001
Comorbidity 0.17 −0.80 to 1.14 0.73
bDMARD, biological disease- modifying antirheumatic drug; 
BMI, Body Mass Index; csDMARD, conventional synthetic 
disease- modifying antirheumatic drug; CDAI, Clinical Disease 
Activity Index; ESR, erythrocyte sedimentation rate; HAQ, 
Health Assessment Questionnaire; MTX, methotrexate; TCZ- IV, 
intravenous tocilizumab; TCZ- SC, subcutaneous tocilizumab.
At 1 year, 1525 TCZ- IV and 524 TCZ- SC patients were 
still under treatment. Among them, 13.9% of TCZ- IV and 
15.3% of TCZ- SC patients were in CDAI remission, 56.8% 
and 61.5% in CDAI not in remission but LDA, 56.6% 
and 63.4% in DAS28 remission, and 20.9% and 19.6% in 
DAS28 not in remission but LDA, respectively. There were 
no statistically significant differences in these responses 
rates between TCZ- SC and TCZ- IV except for the DAS28 
remission, which was slightly higher in the TCZ- SC group 
(p=0.03), even after correction for attrition with the 
LUNDEX (figure 3, CDAI remission: 10.6% in TCZ- IV 
vs 11.1% in TCZ- SC (difference: 0.5%, bootstrap 95% CI 
−1.9% to 4.0%); CDAI LDA: 42.9% in TCZ- IV vs 44.5% 
in TCZ- SC (difference: 1.5%, bootstrap 95% CI −1.1% 
to 8.2%); DAS28 remission: 42.8% in TCZ- IV vs 45.8% 
in TCZ- SC (difference: 3.0%, bootstrap 95% CI 0.4 to 
9.6); DAS28 LDA: 15.8% in TCZ- IV vs 14.2% in TCZ- SC 
(difference: −1.7%, bootstrap 95% CI −4.2 to 2.5)). After 
matching, there was no longer a significant difference 
of ESR and HAQ between the groups with 560 patients 
in each group (online supplementary table S5). From 
those, LUNDEX- corrected CDAI remission at 1 year in 
the matched population were not significantly different 
between TCZ- SC and TCZ- IV patients (CDAI remission: 
10.4% in TCZ- IV vs 12.8% in TCZ- SC (difference: 2.4%, 
bootstrap 95% CI −2.1% to 7.6 %)), but CDAI LDA rates 
were higher in the TCZ- SC patients: 41.0% in TCZ- IV 
versus 49.1% in TCZ- SC (difference: 8.0%; bootstrap 
95% CI 2.4% to 17.6%). The results were similar when 
including only patients since 2014, but CDAI LDA rates 
were not significantly different between TCZ- IV- only and 
TCZ- SC- only patients. CDAI remission and LDA rates 
were also similar between BMI categories, and there 
was no significant difference in the LUNDEX- corrected 
CDAI remission and LDA when comparing TCZ- IV and 
TCZ- SC by categories of BMI.
For TCZIV2SC patients, the median time to switch was 
2.21 years, 95% CI 0.92 to 3.47, and the median time of 
follow- up after switch was 1.16 years, 95% CI 0.08 to 2.56. 
For TCZSC2IV patients, the median time to switch was 
0.5 years, 95% CI 0.06 to 1.14, and the median time of 
follow- up after switch was 0.36 years, 95% CI 0.08 to 1.13. 
CDAI decreased from baseline until the patients switched 
to the other route of administration and continued to 
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Figure 3 LUNDEX- corrected Clinical Disease Activity Index (CDAI) and Disease Activity Score 28 (DAS28) remission and low 
disease activity (LDA). TCZ- IV, intravenous tocilizumab; TCZ- SC, subcutaneous tocilizumab.
decrease thereafter in a manner similar to the patients 
who did not switch (online supplementary table S6).
In patients where the reason for stopping the drug was 
collected, 35% in TCZ- SC stopped for adverse events, 36% 
for ineffectiveness and 28% for other reasons (which may 
include a combination of reasons, pregnancy or remis-
sion). In the TCZ- IV group, more patients stopped for 
other reason (34%) and ineffectiveness (36%) than for 
adverse events (26%). However, the cause of treatment 
discontinuation was not provided in more than 50% 
of patients in each group (56% in TCZ- IV and 75% in 
TCZ- SC).
dIsCussIOn
Our study is the first to compare TCZ- SC versus TCZ- IV 
in a real- world RA population. The results show that 
even if the crude drug discontinuation rate was very 
different, after adjustment, drug retention and clinical 
effectiveness, as assessed by CDAI and DAS28 changes 
and responses, were similar between TCZ- SC and TCZ- IV. 
These data indicate that TCZ- SC is an adequate alterna-
tive to TCZ- IV and confirm previous results from clinical 
trials in a large observational setting.6 7 To note, CDAI 
LDA was slightly higher in the TCZ- SC group.
Concerning the patient population, baseline demo-
graphic characteristics were very similar, but TCZ- IV 
patients had higher disease activity in terms of DAS28, 
HAQ, TJC, SJC, ESR and CRP. This may be linked to a 
channelling bias with TCZ- IV prescribed for more severe 
patients or to the fact that patients received TCZ- IV at 
an earlier period, when less alternatives were available 
and less accent was put on the treat- to- target strategy,17 
leading to overall higher disease activity. Despite these 
baseline characteristics’ differences, the effectiveness was 
similar between TCZ- IV and TCZ- SC.
The difference in the crude retention between TCZ- SC 
and TCZ- IV was mainly associated to the treatment year 
of initiation. This important confounding effect of the 
calendar year has been described several times before in 
registries data and may be linked to the increased possi-
bility of treatment or different expectations from the 
patients and physicians.18–20
As described before in TCZ and other bDMARDs, we 
found that a higher HAQ and disease activity at base-
line were associated with higher discontinuation.19–21 
Co- therapy with a csDMARD, especially MTX, was associ-
ated with a higher CDAI and DAS28 at any point during 
follow- up. This may be linked to a residual confounding 
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effect of severity, patients with co- therapy having higher 
parameters of disease activity and severity at baseline 
(higher DAS28, PGA, PhGA, TJC and number of previous 
bDMARDs).
In our cohort, seropositivity was associated to a lower 
CDAI at any time during follow- up. A higher remission 
rate has been described in RF- positive patients treated with 
TCZ, but this was not reproduced in ACPA- positive patients 
in another cohort.22 23
Retention was higher with TCZ- IV2SC than TCZ- IV- only 
patients. Unfortunately, our data did not allow us to eval-
uate the reasons of switching between routes of delivery. 
It is possible that this reflects a selected population with 
better effectiveness, tolerance and compliance, who 
switched for practical reasons but were already considered 
as responders. These results are in line with two previous 
studies looking at patients switching from TCZ- IV to TCZ- 
SC. In the 84- week, open- label extension of the MUSASHI 
trial, 160 patients switched from TCZ- IV to TCZ- SC and 
efficacy was maintained after switch.24 Another small trial 
with 57 Japanese patients did not find a change of efficacy 
after switching from TCZ- IV to TCZ- SC after a follow- up 
of 3 months.25 However, our study is the first to evaluate 
switching from TCZ- IV to TCZ- SC in a large non- Japanese 
population. In the TCZ- SC2IV subgroup, the descriptive 
analysis of CDAI also showed a similar trend in efficacy 
before and after switch than other subgroups; however, the 
TCZ- SC2IV subgroup was too small and the duration of 
follow- up too short to draw any definitive conclusion.
As in previous studies, we did not find an effect of BMI 
on both TCZ formulations as assessed by drug retention 
or clinical effectiveness.25–27
Our study has several limitations. Data quality of registries 
is often less thorough than in clinical trials. In particular, 
we do not have enough details on causes of discontinu-
ation or switching to allow further analysis. We have also 
no data on adherence that may be different between the 
TCZ- IV and TCZ- SC. Adherence is reported to be lower 
with subcutaneous bDMARDs and more frequent dosing 
schedule.28 29 Despite this, we did not find a difference in 
effectiveness when comparing TCZ- SC with TCZ- IV. Finally, 
we do not have data outside of the bDMARDs courses and 
thus could not explore other aspects as for example the 
rate of biologic- free remission between groups.
The strengths of this study is that we have a large popu-
lation and number of covariates, a longer duration of 
follow- up and an observational setting which allow less 
strict inclusion criteria than in previous clinical trials who 
compared TCZ- SC with TCZ- IV.
In conclusion, our study shows that TCZ- SC is an 
adequate alternative to TCZ- IV in RA. Thus, when possible 
and considering the costs of administration of TCZ- IV, 
TCZ- SC should be the preferred mode of administration.
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The article has been corrected since it was published online. The values in the 
second row “Total patient- years” of table 1 have been amended and the supplement 
file has been updated to support the same.
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